Interpretation of price changes and patient burden of Tepotinib (Tuodekang) after medical insurance

Tepotinib, a targeted drug for MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC), has been launched in China and has been successfully included in the medical insurance system. This policy enables patients to obtain a certain percentage of reimbursement when purchasing drugs, thereby significantly reducing the financial burden. The price of the original drug is relatively high, about more than 30,000 yuan, but with medical insurance coverage, patients’ actual out-of-pocket expenses will be significantly reduced, helping more qualified patients to receive standardized treatment.

Before the implementation of the domestic medical insurance reimbursement policy, patients were under great pressure to bear the cost of tepotinib themselves, especially in the case of long-term maintenance medication, where the total cost was high. After being included in medical insurance, patients can not only purchase drugs regularly in hospital pharmacies, but also reduce their financial burden through medical insurance reimbursement, significantly improving drug accessibility. This is undoubtedly a major benefit for patients with advanced or metastatic MET exon 14 mutated NSCLC.

In contrast, there are more affordable generic tepotinib drugs on the foreign market, mainly produced by companies such as Laos Lucius and Laos Big Bear. Recently, the prices of these generic drugs have been significantly reduced. The price of 500mg drugs is about more than 6,000 yuan, and the drug ingredients are basically the same as the domestic original drugs. For some patients, obtaining generic drugs through formal overseas channels can further reduce the financial burden while ensuring continuity of medication and therapeutic effects.
Taken together, after Tepotinib is included in medical insurance, the burden on domestic patients will be significantly reduced, especially for patients who require long-term maintenance treatment. At the same time, the existence of overseas generic drugs provides complementary options for patients with limited financial conditions. When choosing drugs, patients should combine their own financial situation, medical insurance policy and doctor's advice to ensure an individualized treatment plan that is both safe and standardized, and affordable.
Reference link: https://www.drugs.com